139 related articles for article (PubMed ID: 23546019)
1. Acquired irinotecan resistance is accompanied by stable modifications of cell cycle dynamics independent of MSI status.
Petitprez A; Poindessous V; Ouaret D; Regairaz M; Bastian G; Guérin E; Escargueil AE; Larsen AK
Int J Oncol; 2013 May; 42(5):1644-53. PubMed ID: 23546019
[TBL] [Abstract][Full Text] [Related]
2. The use of Olaparib (AZD2281) potentiates SN-38 cytotoxicity in colon cancer cells by indirect inhibition of Rad51-mediated repair of DNA double-strand breaks.
Tahara M; Inoue T; Sato F; Miyakura Y; Horie H; Yasuda Y; Fujii H; Kotake K; Sugano K
Mol Cancer Ther; 2014 May; 13(5):1170-80. PubMed ID: 24577941
[TBL] [Abstract][Full Text] [Related]
3. New Topoisomerase I mutations are associated with resistance to camptothecin.
Gongora C; Vezzio-Vie N; Tuduri S; Denis V; Causse A; Auzanneau C; Collod-Beroud G; Coquelle A; Pasero P; Pourquier P; Martineau P; Del Rio M
Mol Cancer; 2011 May; 10():64. PubMed ID: 21619602
[TBL] [Abstract][Full Text] [Related]
4. Characterization of DNA topoisomerase I in three SN-38 resistant human colon cancer cell lines reveals a new pair of resistance-associated mutations.
Jensen NF; Agama K; Roy A; Smith DH; Pfister TD; Rømer MU; Zhang HL; Doroshow JH; Knudsen BR; Stenvang J; Brünner N; Pommier Y
J Exp Clin Cancer Res; 2016 Mar; 35():56. PubMed ID: 27029323
[TBL] [Abstract][Full Text] [Related]
5. The role of the DNA mismatch repair system in the cytotoxicity of the topoisomerase inhibitors camptothecin and etoposide to human colorectal cancer cells.
Jacob S; Aguado M; Fallik D; Praz F
Cancer Res; 2001 Sep; 61(17):6555-62. PubMed ID: 11522654
[TBL] [Abstract][Full Text] [Related]
6. Novel missense mutation of the DNA topoisomerase I gene in SN-38-resistant DLD-1 cells.
Arakawa Y; Suzuki H; Saito S; Yamada H
Mol Cancer Ther; 2006 Mar; 5(3):502-8. PubMed ID: 16546964
[TBL] [Abstract][Full Text] [Related]
7. Determinants of the cytotoxicity of irinotecan in two human colorectal tumor cell lines.
Pavillard V; Agostini C; Richard S; Charasson V; Montaudon D; Robert J
Cancer Chemother Pharmacol; 2002 Apr; 49(4):329-35. PubMed ID: 11914913
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic changes in histone acetylation underpin resistance to the topoisomerase I inhibitor irinotecan.
Meisenberg C; Ashour ME; El-Shafie L; Liao C; Hodgson A; Pilborough A; Khurram SA; Downs JA; Ward SE; El-Khamisy SF
Nucleic Acids Res; 2017 Feb; 45(3):1159-1176. PubMed ID: 28180300
[TBL] [Abstract][Full Text] [Related]
9. Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer.
Fallik D; Borrini F; Boige V; Viguier J; Jacob S; Miquel C; Sabourin JC; Ducreux M; Praz F
Cancer Res; 2003 Sep; 63(18):5738-44. PubMed ID: 14522894
[TBL] [Abstract][Full Text] [Related]
10. Novel stable camptothecin derivatives replacing the E-ring lactone by a ketone function are potent inhibitors of topoisomerase I and promising antitumor drugs.
Lansiaux A; Léonce S; Kraus-Berthier L; Bal-Mahieu C; Mazinghien R; Didier S; David-Cordonnier MH; Hautefaye P; Lavielle G; Bailly C; Hickman JA; Pierré A
Mol Pharmacol; 2007 Aug; 72(2):311-9. PubMed ID: 17494837
[TBL] [Abstract][Full Text] [Related]
11. Chk1 signaling pathways that mediated G(2)M checkpoint in relation to the cellular resistance to the novel topoisomerase I poison BNP1350.
Yin MB; Hapke G; Wu J; Azrak RG; Frank C; Wrzosek C; Rustum YM
Biochem Biophys Res Commun; 2002 Jul; 295(2):435-44. PubMed ID: 12150968
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic mechanisms of irinotecan sensitivity in colorectal cancer cell lines.
Crea F; Giovannetti E; Cortesi F; Mey V; Nannizzi S; Gallegos Ruiz MI; Ricciardi S; Del Tacca M; Peters GJ; Danesi R
Mol Cancer Ther; 2009 Jul; 8(7):1964-73. PubMed ID: 19531575
[TBL] [Abstract][Full Text] [Related]
13. Increased anticancer activity of the thymidylate synthase inhibitor BGC9331 combined with the topoisomerase I inhibitor SN-38 in human colorectal and breast cancer cells: induction of apoptosis and ROCK cleavage through caspase-3-dependent and -independent mechanisms.
Coudray AM; Louvet C; Kornprobst M; Raymond E; André T; Tournigand C; Faivre S; De Gramont A; Larsen AK; Gespach C
Int J Oncol; 2005 Aug; 27(2):553-61. PubMed ID: 16010439
[TBL] [Abstract][Full Text] [Related]
14. Synergistic antitumor activity of the novel SN-38-incorporating polymeric micelles, NK012, combined with 5-fluorouracil in a mouse model of colorectal cancer, as compared with that of irinotecan plus 5-fluorouracil.
Nakajima TE; Yasunaga M; Kano Y; Koizumi F; Kato K; Hamaguchi T; Yamada Y; Shirao K; Shimada Y; Matsumura Y
Int J Cancer; 2008 May; 122(9):2148-53. PubMed ID: 18196580
[TBL] [Abstract][Full Text] [Related]
15. Thymidine selectively enhances growth suppressive effects of camptothecin/irinotecan in MSI+ cells and tumors containing a mutation of MRE11.
Rodriguez R; Hansen LT; Phear G; Scorah J; Spang-Thomsen M; Cox A; Helleday T; Meuth M
Clin Cancer Res; 2008 Sep; 14(17):5476-83. PubMed ID: 18765539
[TBL] [Abstract][Full Text] [Related]
16. Potentiation of cytotoxicity of topoisomerase i poison by concurrent and sequential treatment with the checkpoint inhibitor UCN-01 involves disparate mechanisms resulting in either p53-independent clonogenic suppression or p53-dependent mitotic catastrophe.
Tse AN; Schwartz GK
Cancer Res; 2004 Sep; 64(18):6635-44. PubMed ID: 15374978
[TBL] [Abstract][Full Text] [Related]
17. Irinotecan resistance is accompanied by upregulation of EGFR and Src signaling in human cancer models.
Petitprez A; Larsen AK
Curr Pharm Des; 2013; 19(5):958-64. PubMed ID: 22973964
[TBL] [Abstract][Full Text] [Related]
18. A novel oral camptothecin analog, gimatecan, exhibits superior antitumor efficacy than irinotecan toward esophageal squamous cell carcinoma in vitro and in vivo.
Zou J; Li S; Chen Z; Lu Z; Gao J; Zou J; Lin X; Li Y; Zhang C; Shen L
Cell Death Dis; 2018 May; 9(6):661. PubMed ID: 29855512
[TBL] [Abstract][Full Text] [Related]
19. Anticancer effect of SN-38 on colon cancer cell lines with different metastatic potential.
Wallin A; Svanvik J; Holmlund B; Ferreud L; Sun XF
Oncol Rep; 2008 Jun; 19(6):1493-8. PubMed ID: 18497955
[TBL] [Abstract][Full Text] [Related]
20. Identification of Sestrin3 Involved in the In vitro Resistance of Colorectal Cancer Cells to Irinotecan.
Choi SH; Hong HK; Cho YB; Lee WY; Yoo HY
PLoS One; 2015; 10(5):e0126830. PubMed ID: 25973791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
